Miguel A Ortega, Diego Liviu Boaru, Diego De Leon-Oliva, Oscar Fraile-Martinez, Cielo García-Montero, Laura Rios, Maria J Garrido-Gil, Silvestra Barrena-Blázquez, Ana M Minaya-Bravo, Antonio Rios-Parra, Melchor Álvarez-Mon, Laura Jiménez-Álvarez, Laura López-González, Luis G Guijarro, Raul Diaz, Miguel A Saez
{"title":"PD-1/PD-L1 轴:对免疫调节、癌症进展和转化应用的影响。","authors":"Miguel A Ortega, Diego Liviu Boaru, Diego De Leon-Oliva, Oscar Fraile-Martinez, Cielo García-Montero, Laura Rios, Maria J Garrido-Gil, Silvestra Barrena-Blázquez, Ana M Minaya-Bravo, Antonio Rios-Parra, Melchor Álvarez-Mon, Laura Jiménez-Álvarez, Laura López-González, Luis G Guijarro, Raul Diaz, Miguel A Saez","doi":"10.1007/s00109-024-02463-3","DOIUrl":null,"url":null,"abstract":"<p><p>The PD-1/PD-L1 axis is a complex signaling pathway that has an important role in the immune system cells. Programmed cell death protein 1 (PD-1) acts as an immune checkpoint on the T lymphocytes, B lymphocytes, natural killer (NK), macrophages, dendritic cells (DCs), monocytes, and myeloid cells. Its ligand, the programmed cell death 1 ligand (PD-L1), is expressed in the surface of the antigen-presenting cells (APCs). The binding of both promotes the downregulation of the T cell response to ensure the activation to prevent the onset of chronic immune inflammation. This axis in the tumor microenvironment (TME) performs a crucial role in the tumor progression and the escape of the tumor by neutralizing the immune system, the engagement of PD-L1 with PD-1 in the T cell causes dysfunctions, neutralization, and exhaustion, providing the tumor mass production. This review will provide a comprehensive overview of the functions of the PD-1/PD-L1 system in immune function, cancer, and the potential therapeutic implications of the PD-1/PD-L1 pathway for cancer management.</p>","PeriodicalId":50127,"journal":{"name":"Journal of Molecular Medicine-Jmm","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.\",\"authors\":\"Miguel A Ortega, Diego Liviu Boaru, Diego De Leon-Oliva, Oscar Fraile-Martinez, Cielo García-Montero, Laura Rios, Maria J Garrido-Gil, Silvestra Barrena-Blázquez, Ana M Minaya-Bravo, Antonio Rios-Parra, Melchor Álvarez-Mon, Laura Jiménez-Álvarez, Laura López-González, Luis G Guijarro, Raul Diaz, Miguel A Saez\",\"doi\":\"10.1007/s00109-024-02463-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The PD-1/PD-L1 axis is a complex signaling pathway that has an important role in the immune system cells. Programmed cell death protein 1 (PD-1) acts as an immune checkpoint on the T lymphocytes, B lymphocytes, natural killer (NK), macrophages, dendritic cells (DCs), monocytes, and myeloid cells. Its ligand, the programmed cell death 1 ligand (PD-L1), is expressed in the surface of the antigen-presenting cells (APCs). The binding of both promotes the downregulation of the T cell response to ensure the activation to prevent the onset of chronic immune inflammation. This axis in the tumor microenvironment (TME) performs a crucial role in the tumor progression and the escape of the tumor by neutralizing the immune system, the engagement of PD-L1 with PD-1 in the T cell causes dysfunctions, neutralization, and exhaustion, providing the tumor mass production. This review will provide a comprehensive overview of the functions of the PD-1/PD-L1 system in immune function, cancer, and the potential therapeutic implications of the PD-1/PD-L1 pathway for cancer management.</p>\",\"PeriodicalId\":50127,\"journal\":{\"name\":\"Journal of Molecular Medicine-Jmm\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Molecular Medicine-Jmm\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00109-024-02463-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Medicine-Jmm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00109-024-02463-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
摘要
PD-1/PD-L1轴是一种复杂的信号通路,在免疫系统细胞中发挥着重要作用。程序性细胞死亡蛋白 1(PD-1)是 T 淋巴细胞、B 淋巴细胞、自然杀伤细胞(NK)、巨噬细胞、树突状细胞(DC)、单核细胞和骨髓细胞的免疫检查点。它的配体--程序性细胞死亡 1 配体(PD-L1)在抗原递呈细胞(APC)表面表达。两者的结合会促进 T 细胞反应的下调,以确保活化,防止慢性免疫炎症的发生。肿瘤微环境(TME)中的这一轴在肿瘤进展和肿瘤通过中和免疫系统逃逸方面发挥着至关重要的作用,T细胞中的PD-L1与PD-1啮合会导致功能障碍、中和和衰竭,从而为肿瘤的大量生成提供条件。本综述将全面概述 PD-1/PD-L1 系统在免疫功能、癌症中的功能,以及 PD-1/PD-L1 通路对癌症治疗的潜在治疗意义。
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.
The PD-1/PD-L1 axis is a complex signaling pathway that has an important role in the immune system cells. Programmed cell death protein 1 (PD-1) acts as an immune checkpoint on the T lymphocytes, B lymphocytes, natural killer (NK), macrophages, dendritic cells (DCs), monocytes, and myeloid cells. Its ligand, the programmed cell death 1 ligand (PD-L1), is expressed in the surface of the antigen-presenting cells (APCs). The binding of both promotes the downregulation of the T cell response to ensure the activation to prevent the onset of chronic immune inflammation. This axis in the tumor microenvironment (TME) performs a crucial role in the tumor progression and the escape of the tumor by neutralizing the immune system, the engagement of PD-L1 with PD-1 in the T cell causes dysfunctions, neutralization, and exhaustion, providing the tumor mass production. This review will provide a comprehensive overview of the functions of the PD-1/PD-L1 system in immune function, cancer, and the potential therapeutic implications of the PD-1/PD-L1 pathway for cancer management.
期刊介绍:
The Journal of Molecular Medicine publishes original research articles and review articles that range from basic findings in mechanisms of disease pathogenesis to therapy. The focus includes all human diseases, including but not limited to:
Aging, angiogenesis, autoimmune diseases as well as other inflammatory diseases, cancer, cardiovascular diseases, development and differentiation, endocrinology, gastrointestinal diseases and hepatology, genetics and epigenetics, hematology, hypoxia research, immunology, infectious diseases, metabolic disorders, neuroscience of diseases, -omics based disease research, regenerative medicine, and stem cell research.
Studies solely based on cell lines will not be considered. Studies that are based on model organisms will be considered as long as they are directly relevant to human disease.